相关实验视频
Updated: Jun 13, 2025

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
21.9K
对于缺血性中风患者的阿司匹林-克洛皮多格雷尔联合治疗:在资源较少的环境中进行临床疗效和成本效益分析
Najmiatul Fitria1, Dian Febiana2, Muhammad Akram3
1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Andalas, Padang, Indonesia.
Narra J
|September 16, 2024
概括
阿司匹林-克洛皮多格雷尔组合治疗比单独使用阿司匹林治疗缺血性中风更具成本效益,以更低的成本显示出更好的临床结果. 这种双重疗法为中风管理提供了有利的替代方案.
科学领域:
- 药物经济学 药物经济学
- 临床医学 临床医学
- 心血管研究研究心血管研究
背景情况:
- 缺血性中风的管理需要评估治疗的成本效益.
- 阿司匹林-克洛皮多格雷尔联合治疗是一种阿司匹林单一治疗的替代方案.
- 凝血参数如PT和APTT是关键的临床指标.
研究的目的:
- 评估阿司匹林-克洛皮多格雷尔组合与仅用阿司匹林治疗缺血性中风的成本效益.
- 评估对凝血参数 (PT,APTT) 的临床影响.
- 从医院的角度分析直接的医疗成本.
主要方法:
- 观察性研究比较住院病人缺血性中风病例.
- 直接医疗成本和凝血参数 (PT,APTT) 的分析.
- 不使用折扣的增量成本效益比率 (ICER) 计算.
主要成果:
- 阿司匹林-克洛皮多格雷尔联合治疗显示出更高的成本效益.
- ICER值表示占主导地位:PT (IDR -246,930/秒) 和APTT (IDR -119,270/秒). 这两种值均为主导.
- 组合疗法以更低的成本产生了更好的临床参数值.
结论:
- 阿司匹林-克洛皮多格雷尔联合治疗是缺血性中风的主要和成本有效的策略.
- 这些发现表明,常规中风管理具有潜在的经济和临床优势.
- 组合疗法为临床实践提供了一个有利的替代方案.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Anticoagulant Drugs: Low-Molecular-Weight Heparins
652
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
652
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K

